Cowen and Company reiterated their buy rating on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a report issued on Friday. The firm currently has a $49.00 price target on the biopharmaceutical company’s stock.
JUNO has been the topic of a number of other research reports. Morgan Stanley reissued an equal weight rating and issued a $43.00 price objective (up previously from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Vetr raised shares of Juno Therapeutics from a strong sell rating to a sell rating and set a $25.50 price objective on the stock in a report on Monday, August 14th. Zacks Investment Research downgraded shares of Juno Therapeutics from a hold rating to a sell rating in a report on Monday, August 28th. Raymond James Financial, Inc. raised shares of Juno Therapeutics from a market perform rating to an outperform rating and set a $45.00 price objective on the stock in a report on Tuesday, August 29th. Finally, Barclays PLC started coverage on shares of Juno Therapeutics in a report on Wednesday, September 6th. They issued an overweight rating and a $55.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. Juno Therapeutics presently has an average rating of Hold and an average target price of $38.64.
Shares of Juno Therapeutics (JUNO) traded up 1.3683% during mid-day trading on Friday, hitting $46.3456. 1,363,738 shares of the company were exchanged. Juno Therapeutics has a 52 week low of $17.52 and a 52 week high of $48.14. The company has a 50 day moving average of $43.75 and a 200 day moving average of $31.71. The company’s market capitalization is $4.86 billion.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). The business had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The business’s quarterly revenue was down 22.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.64) EPS. Equities analysts anticipate that Juno Therapeutics will post ($3.08) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Cowen and Company Reaffirms Buy Rating for Juno Therapeutics, Inc. (JUNO)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/10/30/cowen-and-company-reaffirms-buy-rating-for-juno-therapeutics-inc-juno.html.
In other news, EVP Robert Azelby sold 12,869 shares of the business’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $39.95, for a total value of $514,116.55. Following the transaction, the executive vice president now owns 50,289 shares of the company’s stock, valued at $2,009,045.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard Klausner sold 12,000 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $30.34, for a total transaction of $364,080.00. Following the completion of the transaction, the director now directly owns 788,985 shares in the company, valued at approximately $23,937,804.90. The disclosure for this sale can be found here. Insiders have sold 85,004 shares of company stock worth $3,551,561 in the last ninety days. Insiders own 15.26% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares in the last quarter. Pacad Investment Ltd. purchased a new position in shares of Juno Therapeutics in the second quarter worth $105,000. QS Investors LLC purchased a new position in shares of Juno Therapeutics in the second quarter worth $135,000. Macquarie Group Ltd. purchased a new position in shares of Juno Therapeutics in the second quarter worth $248,000. Finally, Leisure Capital Management purchased a new position in shares of Juno Therapeutics in the second quarter worth $255,000. 67.18% of the stock is currently owned by hedge funds and other institutional investors.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
What are top analysts saying about Juno Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics Inc. and related companies.